{"id":35248,"date":"2025-06-16T12:55:39","date_gmt":"2025-06-16T04:55:39","guid":{"rendered":"https:\/\/flcube.com\/?p=35248"},"modified":"2025-06-16T12:55:40","modified_gmt":"2025-06-16T04:55:40","slug":"astrazeneca-launches-truqap-in-china-for-pik3ca-akt1-pten-altered-breast-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35248","title":{"rendered":"AstraZeneca Launches Truqap in China for PIK3CA\/AKT1\/PTEN-Altered Breast Cancer"},"content":{"rendered":"\n

UK-based pharmaceutical giant AstraZeneca\u00a0(AZ, NASDAQ: AZN<\/a>) announced the official commercial launch of Truqap (capivasertib) in China. Approved in April 2024, the drug is indicated for adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer with PIK3CA\/AKT1\/PTEN alterations. It is designed for patients who have experienced disease progression following at least one line of endocrine therapy in the metastatic setting or recurrence within 12 months of completing adjuvant therapy.<\/p>\n\n\n\n

Market First<\/strong>
Capivasertib is the first and only AKT inhibitor approved in China for breast cancer patients with PIK3CA, AKT1, or PTEN alterations.<\/p>\n\n\n\n

Clinical Results<\/strong>
Clinical data demonstrate that the capivasertib\/fulvestrant combination reduces the risk of disease progression or death by 59% compared to fulvestrant alone. In Chinese patients with PIK3CA\/AKT1\/PTEN alterations, the median progression-free survival (PFS) was 5.7 months versus 1.9 months for fulvestrant alone.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

UK-based pharmaceutical giant AstraZeneca\u00a0(AZ, NASDAQ: AZN) announced the official commercial launch of Truqap (capivasertib) in…<\/p>\n","protected":false},"author":1,"featured_media":35249,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[770,40,871],"class_list":["post-35248","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-az","tag-market-launch","tag-nasdaq-azn"],"yoast_head":"\nAstraZeneca Launches Truqap in China for PIK3CA\/AKT1\/PTEN-Altered Breast Cancer - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based pharmaceutical giant AstraZeneca\u00a0(AZ, NASDAQ: AZN) announced the official commercial launch of Truqap (capivasertib) in China. Approved in April 2024, the drug is indicated for adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer with PIK3CA\/AKT1\/PTEN alterations. It is designed for patients who have experienced disease progression following at least one line of endocrine therapy in the metastatic setting or recurrence within 12 months of completing adjuvant therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35248\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca Launches Truqap in China for PIK3CA\/AKT1\/PTEN-Altered Breast Cancer\" \/>\n<meta property=\"og:description\" content=\"UK-based pharmaceutical giant AstraZeneca\u00a0(AZ, NASDAQ: AZN) announced the official commercial launch of Truqap (capivasertib) in China. Approved in April 2024, the drug is indicated for adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer with PIK3CA\/AKT1\/PTEN alterations. It is designed for patients who have experienced disease progression following at least one line of endocrine therapy in the metastatic setting or recurrence within 12 months of completing adjuvant therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35248\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-16T04:55:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-16T04:55:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1606.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35248#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35248\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca Launches Truqap in China for PIK3CA\\\/AKT1\\\/PTEN-Altered Breast Cancer\",\"datePublished\":\"2025-06-16T04:55:39+00:00\",\"dateModified\":\"2025-06-16T04:55:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35248\"},\"wordCount\":160,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35248#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1606.webp\",\"keywords\":[\"AZ\",\"Market launch\",\"NASDAQ: AZN\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35248#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35248\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35248\",\"name\":\"AstraZeneca Launches Truqap in China for PIK3CA\\\/AKT1\\\/PTEN-Altered Breast Cancer - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35248#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35248#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1606.webp\",\"datePublished\":\"2025-06-16T04:55:39+00:00\",\"dateModified\":\"2025-06-16T04:55:40+00:00\",\"description\":\"UK-based pharmaceutical giant AstraZeneca\u00a0(AZ, NASDAQ: AZN) announced the official commercial launch of Truqap (capivasertib) in China. Approved in April 2024, the drug is indicated for adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer with PIK3CA\\\/AKT1\\\/PTEN alterations. It is designed for patients who have experienced disease progression following at least one line of endocrine therapy in the metastatic setting or recurrence within 12 months of completing adjuvant therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35248#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35248\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35248#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1606.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1606.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca Launches Truqap in China for PIK3CA\\\/AKT1\\\/PTEN-Altered Breast Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35248#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca Launches Truqap in China for PIK3CA\\\/AKT1\\\/PTEN-Altered Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca Launches Truqap in China for PIK3CA\/AKT1\/PTEN-Altered Breast Cancer - Insight, China's Pharmaceutical Industry","description":"UK-based pharmaceutical giant AstraZeneca\u00a0(AZ, NASDAQ: AZN) announced the official commercial launch of Truqap (capivasertib) in China. Approved in April 2024, the drug is indicated for adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer with PIK3CA\/AKT1\/PTEN alterations. It is designed for patients who have experienced disease progression following at least one line of endocrine therapy in the metastatic setting or recurrence within 12 months of completing adjuvant therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35248","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca Launches Truqap in China for PIK3CA\/AKT1\/PTEN-Altered Breast Cancer","og_description":"UK-based pharmaceutical giant AstraZeneca\u00a0(AZ, NASDAQ: AZN) announced the official commercial launch of Truqap (capivasertib) in China. Approved in April 2024, the drug is indicated for adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer with PIK3CA\/AKT1\/PTEN alterations. It is designed for patients who have experienced disease progression following at least one line of endocrine therapy in the metastatic setting or recurrence within 12 months of completing adjuvant therapy.","og_url":"https:\/\/flcube.com\/?p=35248","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-16T04:55:39+00:00","article_modified_time":"2025-06-16T04:55:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1606.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35248#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35248"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca Launches Truqap in China for PIK3CA\/AKT1\/PTEN-Altered Breast Cancer","datePublished":"2025-06-16T04:55:39+00:00","dateModified":"2025-06-16T04:55:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35248"},"wordCount":160,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35248#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1606.webp","keywords":["AZ","Market launch","NASDAQ: AZN"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35248#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35248","url":"https:\/\/flcube.com\/?p=35248","name":"AstraZeneca Launches Truqap in China for PIK3CA\/AKT1\/PTEN-Altered Breast Cancer - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35248#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35248#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1606.webp","datePublished":"2025-06-16T04:55:39+00:00","dateModified":"2025-06-16T04:55:40+00:00","description":"UK-based pharmaceutical giant AstraZeneca\u00a0(AZ, NASDAQ: AZN) announced the official commercial launch of Truqap (capivasertib) in China. Approved in April 2024, the drug is indicated for adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer with PIK3CA\/AKT1\/PTEN alterations. It is designed for patients who have experienced disease progression following at least one line of endocrine therapy in the metastatic setting or recurrence within 12 months of completing adjuvant therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35248#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35248"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35248#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1606.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1606.webp","width":1080,"height":608,"caption":"AstraZeneca Launches Truqap in China for PIK3CA\/AKT1\/PTEN-Altered Breast Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35248#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca Launches Truqap in China for PIK3CA\/AKT1\/PTEN-Altered Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1606.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35248"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35248\/revisions"}],"predecessor-version":[{"id":35250,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35248\/revisions\/35250"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35249"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}